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In spite of the global efforts of the World Health 
Organization (WHO) and partners to reduce the incidence 
of tuberculosis (about 2% per year) and its mortality 
(about 3% per year), the disease is still a global killer and 
has primary public health importance, with an estimate 
of 10.4 million cases in 2016.(1)
The End TB Strategy and its vision (zero tuberculosis-
related deaths, cases, and suffering) underlies the 
possibility to eliminate tuberculosis as a public health 
priority in countries with a low incidence of tuberculosis. (2-4) 
Pillar 2 of the End TB Strategy clearly emphasizes the 
importance of collaboration at different levels. This 
international collaboration represents the last of the 
eight core areas to pursue tuberculosis elimination.(4)
Translating that into simple words, international 
collaboration comprises all of the interactions involving 
clinicians, laboratory staff, public health officers, national 
tuberculosis programs, other programs (HIV/AIDS 
programs and diabetes programs in some countries), 
Ministries of Health (as well as Ministries of Justice for 
jails/prisons, Ministries of Interior for the migration-related 
issues, Ministries of Transportation, etc), private sector, 
pharmaceutical sector, civil society, representatives of the 
affected communities, and international organizations, 
among others.(4,5)
As of today, several TB Networks exist: the Stop TB 
Partnership(6) has a long tradition in supporting advocacy. 
In addition, one of the best examples is the Brazilian Rede 
TB, which shows that the best research efforts, even 
in a large country as is Brazil, can collaborate to solve 
country-specific priorities and involve national tuberculosis 
programs and authorities in the plan.(7-11) However, as 
of today, no global tuberculosis network is operational 
enough to put together all of the abovementioned actors 
in order to support the fight against tuberculosis.
To respond to this need, the Global TB Network* (GTN) 
will be launched at the second Conference of the World 
Association for Infectious Diseases and Immunological 
Disorders (WAidid),(12) which will take place in the city 
of Milan, Italy, from October 18-20 of 2018, involving 
an international group of experts and covering a wide 
range of perspectives.
The goal of the GTN is to pursue tuberculosis elimination 
with a global effort proactively, building on existing 
collaborations in the area of research, advocacy, and 
training. Its core objectives are to foster and conduct 
research on key unmet therapeutic and diagnostic needs 
in the field of tuberculosis elimination, leveraging on 
multidisciplinary, multisectoral approaches and supportive 
interventions (i.e., training and advocacy activities) within 
the framework of the WHO End TB Strategy. Preliminary 
plans propose to focus on latent tuberculosis infection, 
multidrug- and extensively drug-resistant tuberculosis 
rapid diagnosis, and other neglected areas (pediatric 
tuberculosis, extrapulmonary tuberculosis, rehabilitation 
of tuberculosis sequelae, infection control, etc.)
The GTN represents the structured evolution of 
pre-existing global tuberculosis networks, including the 
international linezolid, carbapenems and bedaquiline 
study groups and the International Severe Cases and 
Rehabilitation Study Group, which produced over 40 articles 
in the last five years in impact-factor, peer-reviewed 
journals, as well as various series on tuberculosis in 
different journals in collaboration with scientific societies, 
such as the European Respiratory Society, Sociedade 
Brasileira de Pneumologia e Tisiologia, and the Asociación 
Latinoamericana del Tórax.(13-18)
This new global network aims at collaborating with 
existing organizations, associations, institutions, and 
partners that are committed to fight against tuberculosis 
by complementing and boosting (and not duplicating) 
the existing initiatives.
The GTN is hosted by WAidid,(12) founded in July of 
2014 in order to advance the scientific research in the 
field of infectious diseases and immunology and to 
disseminate information on the related pathologies. 
WAidid is the response to the previous lack of a network 
that links associations and scientific societies focused on 
infections, vaccines, and immunology. WAidid, whose 
membership is free of charge, represents the bridge for a 
global multidisciplinary approach to infections (including 
tuberculosis) operating across all age groups.
The GTN is composed of three pillars:
J Bras Pneumol. 2018; Ahead of Print:0-0
1
EDITORIAL
Global TB Network: working together to eliminate tuberculosis
Pillar 1 includes the Technical Committees 
covering the main areas relevant to tuberculosis 
and nontuberculous mycobacteriosis management 
(Tuberculosis Prevention/Latent Tuberculosis Infection; 
Tuberculosis Diagnosis; Tuberculosis Treatment; 
Tuberculosis Pharmacology; Pediatric Tuberculosis; 
Migrants/Vulnerable Populations; Nontuberculous 
Mycobacteriosis; Tuberculosis Infection Control; 
Impact Evaluation, Strategies & Global Health; Clinical 
Support to Patients (Tuberculosis Consilium); Clinical 
Trials; Tuberculosis and Surgery; Basic Science; and 
Epidemiology, Statistics and Methodology).
Pillar 2 includes representatives from each 
association/organization active in tuberculosis control 
interested in participating in the GTN.
Pillar 3 includes the private and pharmaceutical 
sectors.
Several global projects have already started, including 
an online clinical service aimed at supporting the 
correct management of difficult-to-treat tuberculosis 
cases and of individuals with latent tuberculosis 
infection, as well as the rational introduction of new 
drugs; a project monitoring adverse events of new 
antituberculosis drugs; one study on tuberculosis 
and surgery; and one study on tuberculosis sequelae 
and rehabilitation.
We hope this initiative will contribute to reaching the 
ambitious goals of the End TB Strategy.
*Global TB Network provisional Steering 
Committee:
Chair: Giovanni Battista Migliori
Secretary General: Denise Rossato Silva
Other Members: Jan-Willem Alffenaar, Jeremiah 
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James Chalmers, Sergey Borisov, Erlina Buran, Isabel 
Saraiva,  Masae Kawamura (Observer) 
Global TB Network Secretariat
Secretariat in Tradate (Italy): Rosella Centis, Lia 
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Clinical Support to Patients (TB Consilium): Marina 
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World Association for Infectious Diseases and 
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